Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.57 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ABL1 | P00519 | 10/20 | 0.47 |
| ▸ | BCR | P11274 | 10/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859353 | 1.00 | PRKCA (0.57) | PRKCACAMKK2PIK3CGMAPK8EGFR | |
| SCHEMBL13859343 | 0.89 | EGFR (0.49) | PRKCAEGFRJAK3 | |
| SCHEMBL13859342 | 0.89 | EGFR (0.49) | PRKCAEGFRJAK3 | |
| SCHEMBL13859531 | 0.87 | EGFR (0.51) | PRKCAEGFRJAK3 | |
| SCHEMBL13859529 | 0.87 | EGFR (0.51) | PRKCAEGFRJAK3 | |
| SCHEMBL13859470 | 0.87 | EGFR (0.47) | PRKCACAMKK2PIK3CGMAPK8EGFR | |
| SCHEMBL13859468 | 0.87 | EGFR (0.47) | PRKCACAMKK2PIK3CGMAPK8EGFR | |
| SCHEMBL13859249 | 0.85 | EGFR (0.49) | PRKCACAMKK2PIK3CGMAPK8EGFR | |
| SCHEMBL13859251 | 0.85 | EGFR (0.49) | PRKCACAMKK2PIK3CGMAPK8EGFR | |
| SCHEMBL13859349 | 0.85 | ABL1 (0.52) | PRKCACAMKK2PIK3CGMAPK8ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| EP-2710007-A2 | KINASE INHIBITORS | The Regents of the University of California (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | PRKCA 82/4885CAMKK2 237/4885PIK3CG 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.